14037-86-6

Basic information

• Product Name: 3-bromopropyl 3,4,5-trimethoxybenzoate
• CAS NO: 14037-86-6
• Molecular Formula: C₁₃H₁₇BrO₅
• Molecular Weight: 333.1751
• Mol File: 14037-86-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 368.8°C at 760 mmHg
• Flash Point: 176.9°C
• Density: 1.356g/cm³
• Vapor Pressure: 1.24E-05mmHg at 25°C
• Refractive Index: 1.523
• CAS DataBase Reference: 3-bromopropyl 3,4,5-trimethoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromopropyl 3,4,5-trimethoxybenzoate(14037-86-6)
• EPA Substance Registry System: 3-bromopropyl 3,4,5-trimethoxybenzoate(14037-86-6)

Safety Data

• Hazardous Substances Data: 14037-86-6(Hazardous Substances Data)

Upstream product

• 4521-61-3 3,4,5-Trimethoxybenzoyl chloride 
• 627-18-9 1-bromo-3-propanol 
• 118-41-2 Eudesmic acid 
• 109-64-8 1,3-dibromo-propane 
• 149-91-7 3,4,5-trihydroxybenzoic acid 

Downstream Products

• 119368-70-6 3,4,5-trimethoxy-benzoic acid 3-(1,3,4,9-tetrahydro-β-carbolin-2-yl)-propyl ester 
• 67293-50-9 3,4,5-Trimethoxy-benzoesaeure-[3-(N-aethyl-N-phenaethyl)-amino-propylester] 
• 119078-44-3 1-(1-methyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(3,4,5-trimethoxy-benzoyloxy)-propane 
• 870449-75-5 3,4,5-trimethoxybenzoic acid 3-(4-benzylpiperazin-1-yl)propyl ester 
• 870449-82-4 3,4,5-trimethoxybenzoic acid 3-[[2-(benzylmethylamino)ethyl]methylamino]propyl ester 
• 870449-85-7 3,4,5-trimethoxy-benzoic acid 3-[methyl-(2-methylamino-ethyl)-amino]-propyl ester 
• 53427-06-8 3,4,5-trimethoxybenzoic acid 3-(piperazin-1-yl)propyl ester 
• 56887-39-9 3,4,5-trimethoxy-benzoic acid 3-(4-acetyl-[1,4]diazepan-1-yl)-propyl ester 
• 20153-98-4 dilazep dihydrochloride 
• 54-02-4 3,4,5-trimethoxy-benzoic acid 3,3'-piperazine-1,4-diyl-dipropyl ester 
• 110155-34-5 3,4,5-trimethoxy-benzoic acid-[3-(4-methyl-piperazino)-propylester]; hydrochloride 

Relevant articles and documents

Gallic acid acylated derivatives having anticancer activity and use thereof

The invention discloses gallic acid acylated derivatives having anticancer activity. The gallic acid acylated derivatives have a structural formula shown in the description. The acylated derivatives provided by the invention have good activity to oral cancer cells, have good selectivity and have a good clinical application value.

Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N, N -bis(alkanol)amine aryl esters

As a continuation of our research on potent and efficacious P-gp-dependent multidrug resistance (MDR) reversers, several new N,N-bis(alkanol)amine aryl esters were designed and synthesized, varying the aromatic moieties or the length of the methylenic chain. The new compounds were tested on doxorubicin-resistant erythroleukemia K562 cells (K562/DOX) in the pirarubicin uptake assay, where most of the new compounds were shown to be active. In particular the asymmetrical compounds, characterized by two linkers of different length, generally showed fairly high activities as MDR reversers. Some selected compounds (isomers 15-17) were further studied by evaluating their doxorubicin cytotoxicity enhancement (reversal fold, RF) on the K562/DOX cell line. The results of both pharmacological assays indicate that compounds 16 (GDE6) and 17 (GDE19) could be interesting leads for the development of new P-gp dependent MDR modulators.